iiinova — where your digital self keeps evolving

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 16/09/2026

Registration for Perturb 2027: High-Content CRISPR Screening Conference in NYC is now open! Acquire your ticket at an unbeatable price – and don’t wait too long! Early bird tier tickets are limited until December 15th or to the existing stock (120 tickets). Visit www.perturb2027.bio to learn more.

042

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 10/09/2026

What primary human cell models can we work with at Myllia? Explore our new interactive human body illustration to discover how we apply high-content CRISPR screening across a broad range of therapeutic areas. Have a look here: myllia.com

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 01/09/2026

Myllia is a co-author on "Predicting cellular responses to perturbation across diverse contexts with State" — just published in @cellpress.bsky.social! State is a foundation model predicting how cells respond to genetic & chemical perturbations across diverse contexts (1/2) cell.com/cell/fulltex...

132

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 11/06/2026

Stefanie is heading to Berlin to represent Myllia at Discovery & Development Europe 2026 She will present a poster on how pooled CRISPR screenings were combined with InTraSeq, a single-cell method that measures RNA alongside intracellular and surface proteins. 🔗 shorturl.at/2XihX @cellsignal.com

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 29/05/2026

Two weeks to our Element Biosciences webinar! Tillmann Burckstummer and Jens Durruthy Durruthy will take the stage to discuss how optical pooled CRISPR screens revealed NF-kB regulators in human cells. 📅 June 10th 🕑09:00 PDT/ 12:00 EDT/ 16:00 GMT 🔗https://shorturl.at/3DGEf

022

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 15/05/2026

Myllia is attending SLAS Europe in Vienna! May 19th - Henrik, our VP Commercial, will present Myllia's high-content CRISPR screening platform. May 20th - Tilmann, CSO, will showcase how our VISTA platform deciphers primary human macrophage biology. 🔗https://shorturl.at/PEbuc

021

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 08/05/2026

Meet Myllia Biotechnology at #CIMT2026 in Mainz 🇩🇪 Our Assoc. Director of R&D, Sumit, will present on pooled CRISPR screening for drug target discovery in primary human macrophages—highlighting our VISTA platform. 📅 May 11–13 👉 myllia.com/events/cimt-...

021

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 04/02/2026

🚀 Are you ready to push the boundaries of bio AI foundation models? @mylliabio.bsky.social is thrilled to host "Echoes of Silenced Genes" - A Global Community Prediction Competition! 🔗 Learn more here and join the competition: myllia.com/events/commu... #AI #BioAI #CRISPR #Perturb2026

Myllia's Perturbation Prediction Challenge 2026: Echoes of Silenced Genes - Can you predict how CRISPRi perturbations influence the phenotypes of human cells?

132

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 02/12/2025

Are you interested in single-cell genomics, AI-ready perturbation data and virtual cell models? The registration for the "High-Content CRISPR Screening" conference in March 2026 is open via the website: perturb2026.bio Meet the Speaker: Ci Chu

Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.

021

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 25/11/2025

We’re excited to announce the expansion of Myllia’s commercial team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. At @mylliabio.bsky.social, we’ve built a unique, scalable CRISPR screening platform!

We’re excited to announce the expansion of Myllia’s global commercial leadership team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. Their expertise strengthens our ability to support partners worldwide as we advance next-generation CRISPR screening technologies!

At Myllia Biotechnology, we’ve built a unique, scalable CRISPR screening platform:

- Unbiased drug target discovery powered by high-throughput, pooled CRISPR screening
- Primary human cell models that translate in vivo, e.g., T helper cells and myeloid cells
- Single-cell resolution for deeply resolved functional genomics

Get in touch via info@myllia.com and come join the “High-Content CRISPR Screening” conference in March 2026:

www.perturb2026.bio

#TeamMyllia #CRISPR #FunctionalGenomics #DrugDiscovery

042

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 24/11/2025

Are you interested in single-cell genomics and drug target discovery? The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria. Conference website: perturb2026.bio Meet the Speaker: @thijnbrummel.bsky.social

Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 14/10/2025

Myllia Biotechnology is heading to @elrig.org Drug Discovery 2025! Meet with Lukas Badertscher, Stefanie Fellinger, and Henrik Schmidt to explore CRISPR-based functional genomics for drug target discovery. Spotlight Talk, Day 1, 12.40 PM Posters #3, #45, and #107 Booth D02

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 02/10/2025

Are you interested in single-cell genomics, multi-modal perturbation data and drug target discovery? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria! Meet the Speaker: Radu Rapiteanu www.perturb2026.bio

Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 29/09/2025

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. The registration is now open via the conference website: perturb2026.bio Meet the Speaker: Mathew Garnett @mgarnett.bsky.social

Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 22/09/2025

Meet Myllia's @henrik-hs.bsky.social at #BioJapan2025 in Yokohama, Tokyo from October 8-10 to discuss your next CRISPR-based drug target discovery partnerships! Websites: myllia.com myllia.com/events/bio-j... Contact us via email: info@myllia.com

Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics:

Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships!

At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology.

📰 Visit www.myllia.com for more information
📩 Contact us via email: info@myllia.com

031

Henrik Schmidt @henrik-hs.bsky.social · 08/09/2025

Exciting times ahead for @mylliabio.bsky.social in Q4 2025 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November 📰 Website: www.myllia.com 📩 Contact: info@myllia.com

Meet Myllia at:

📍 BIO Japan 2025 - Tokyo, 8-10 October
📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October
📍 BIO Europe 2025 - Vienna, 3-5 November

021

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 21/08/2025

🧬 Meet #TeamMyllia Our mission is to accelerate drug discovery through high-content CRISPR screening: - 150+ CRISPR screens in cell lines and primary cells - 35+ collaborative projects worldwide - End-to-end workflows from screening to bioinformatics www.myllia.com

At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.

We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:

- 150+ CRISPR screens in cell lines and primary human cells
- 35+ collaborative projects worldwide
- End-to-end workflows from experimental screening to computational analysis

Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays.

👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com

042

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 11/08/2025

📢 @mylliabio.bsky.social is heading to #IUIS2025 - we’re excited to share that Anke Loregger, Myllia’s Director of R&D, will attend the International Congress of Immunology (IUIS) 2025 in Vienna! Interested in the VISTA platform? Poster: II.265 on Wednesday, August 20 at 12.15 PM www.myllia.com

032

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 05/08/2025

🧬 Unlocking target discovery in primary human dendritic cells with VISTA™ At @mylliabio.bsky.social, we’re enabling functional genomics in primary immune cells. Our VISTA™ platform combines pooled CRISPRi with scRNA-Seq to systematically map gene function at scale! Contact us via: info@myllia.com

032

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 07/08/2025

🗓️ @mylliabio.bsky.social sponsors the first conference on "High-Content CRISPR Screening" from March 18-19, 2026 in Vienna: perturb2026.bio Scientific topics: 🔬 CRISPR-based screening strategies 🧬 Perturb-Seq & CROP-Seq 💻 Computational analyses 💻 AI models of human cells 📸 Image-based screens

056

Henrik Schmidt @henrik-hs.bsky.social · 15/04/2025

Looking forward to representing @mylliabio.bsky.social at the #SwissBiotechDay 2025 in Basel and discussing drug target ID/validation powered by single-cell CRISPR screens in primary human cells! 🎯 Explore Myllia's platform: myllia.com 📩 Contact: info@myllia.com #TeamMyllia #CRISPR #scRNASeq

012

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 08/04/2025

We will be at #AACR25 in Chicago, USA Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages" 🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST 🎯 Poster: LB043, Section 52 myllia.com #CRISPR #scRNASeq #TargetDiscovery #FGX

041

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 05/03/2025

🚀 At @mylliabio.bsky.social, we're advancing scRNA-Seq in primary human cells with our targeted sequencing (TA-Seq) platform! Key insights: • TA-Seq uses 10K reads/cell vs. 50K reads/cell for WTA • Low-abundance mRNAs are detected more effectively w/ TA-Seq & multiplexed primer panels myllia.com

021

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 26/02/2025

A team at @mylliabio.bsky.social contributed one of the largest single-cell #CRISPR #perturbation #screens published today: nature.com/articles/s41... The lab of Wei Li developed the perturbation-response score (PS) allowing the quantification of diverse perturbation responses in single cells!

nature.com

Decoding heterogeneous single-cell perturbation responses - Nature Cell Biology

In two independent studies, Song et al. and Jiang, Dalgarno et al. present computational frameworks, perturbation-response score and Mixscale, respectively, to determine individual cellular variation ...

031

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 14/02/2025

🧬 At @mylliabio.bsky.social, we're pushing the boundaries of #scCRISPR screens in primary human T cells. For example, we focus on scalable #CROPSeq screens to uncover key mediators of T helper cell differentiation, particularly Th2 cells! Reach out via: myllia.com/contact/ #CRISPR #scRNASeq #TCells

011

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 11/02/2025

📢 One month to go! @mylliabio.bsky.social will be at #BIOEuropeSpring 2025 in Milan, Italy! Would you like to get in touch? Meet our BD Manager @henrik-hs.bsky.social on site to explore #CRISPR-based #functional #genomics screens in primary human cells! Learn more about CROP-Seq here: myllia.com

052

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 03/02/2025

Can #AI predict #CRISPR perturbation outcomes? @mylliabio.bsky.social's CROP-Seq dataset provides a critical resource for AI-driven #Foundation #Models of the Human Cell: myllia.com/resources/cr... We're the global leader in CRISPR-based functional genomics screens - contact us via info@myllia.com

052

Reposted by Henrik Schmidt

Myllia Biotechnology @mylliabio.bsky.social · 23/01/2025

🔬 At @mylliabio.bsky.social, we're revolutionizing target discovery with CROP-Seq in primary human T cells: - Custom assay development - SLICE protocol for functional screening - Integration of CITE-Seq & scRNA-Seq Ready to elevate your research? Contact us at info@myllia.com and visit: myllia.com

011